Jingxin Pharmaceutical: It has not cooperated with Shiono Pharmaceutical and Pfizer on COVID-19 drugs

2022-08-06 0 By

Jingxin Pharmaceutical released a stock price change announcement on the evening of March 27, noting rumors on the Internet that “the company has the raw material of trifluorobenzoyl chloride novel coronavirus” and “jingxin Pharmaceutical owns the only target of shionoyi/Pfizer novel coronavirus key intermediates”.According to the company, the company’s API drugs are mainly quinolones, statins and neuroleptics. At present, the company and its subsidiaries have not carried out COVID-19 drug cooperation with Shionoyi Pharmaceutical and Pfizer.2,4, 5-trifluorobenzoyl chloride planned for the Shandong base of the company is the key intermediate for the preparation of 2,4, 5-trifluorobenzoyl chloride, which needs a certain period to be put into production. It is expected to have no material impact on the company’s performance in 2022, and the impact on the company’s future performance in subsequent years is highly uncertain.